ArticleFrontiers in veterinary science2025
Use of alteplase continuous rate infusion, pentoxifylline, and cyproheptadine in association or not, in acute feline aortic thromboembolism: a study of nine cats.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surgical treatment and outcomes in feline aortic thromboembolism: a retrospective study of 13 cats.Frontiers in veterinary science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Locomotion improvement without serious complications is the main goal of treatment for feline aortic thromboembolism (FATE). We aimed to describe the survival and functional recovery of cardiogenic FATE treated with tissue plasminogen activator (rtPA) continuous rate infusion (CRI) and/or pentoxifylline (PTX) and/ or cyproheptadine (CYP), and to identify non-survivor characteristics. Methods: This is a retrospective, bicentric case series. Inclusion criteria were cardiogenic FATE cats receiving any of the medications described. Proportions of locomotion recovery, survival to discharge, reperfusion injury (RI) and acute kidney injury (AKI) were described. Admission and outcome characteristics were compared between survivors and non-survivors. Results: Nine cats were identified, 8/9 (88.9%) with bilateral FATE. Median age was 8.2 years (5.3-12.5). Median weight was 5.3 kg (4.1-7.1). Admission rectal temperature, affected limb lactate, creatinine and potassium were 36.9°C (35.4-38.8), 14.2 mmol/L (7.1-18.8), 114.9 umol/L (53-185.6) and 3.7 mmol/L (3.5-44.), respectively. No significant differences were found between survivors and non-survivors for relevant admission characteristics. Seven (77.8%) cats received tPA-CRI, 7/9 (77.8%) cats received pentoxifylline and 5/9 (55.6%) cats received cyproheptadine. Three (33.3%) cats received monotherapy (two rtPA-CRI, one PTX), 2/9 (22.2%) cats received dual therapy (one rtPA-CRI/PTX, one PTX/ CYP) and 4/9 (44.4%) cats received triple therapy. All study cats (100%) had an improvement in locomotion, and 4/9 (44.4%) survived to discharge. Reperfusion injury and AKI were documented in 3/9 (33.3%) and 4/9 (44.4%) of cats, respectively. Non-survivors had a greater proportion of AKI than survivors (4/5 (80%) and 0/4 (0%), respectively). No other outcome characteristics were different between survivors and non-survivors. Discussion: rtPA CRI, PTX and/or CYP could be considered for treatment of FATE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.